Presentation at the UBS Global Life Sciences Conference 2010
(Thomson Reuters ONE) -
21 September 2010, Lysaker, Norway: CEO Morten Jurs in Pronova BioPharma will
give a presentation of the company at the UBS Global Life Sciences Conference
2010 at 12:30 EST at the Grand Hyatt New York in New York City.
The presentation is attached and is also available on http://www.pronova.com.
For further information, please contact:
Hamed Brodersen, vice president IR and communications +47 40 46 81 10
Synne Røine, CFO +47 22 53 49 10
About Pronova BioPharma
Pronova BioPharma is a global leader in the research, development and
manufacture of marine-originated omega-3 derived pharmaceutical products.
Pronova BioPharma is the first and only company with an EU and FDA approved
Omega-3 derived prescription drug. Pronova BioPharma's first commercialized
product is branded as Omacor® in a number of countries throughout Europe and
Asia and as LovazaTM in the United States. The product is manufactured, using a
unique and complex process, at the company's plants in Sandefjord, Norway and
Kalundborg, Denmark.
Omacor®/LovazaTM is the first and only EU- and FDA- approved omega-3 derived
prescription drug. The drug is prescribed as an adjunct to diet for the
treatment of elevated levels of triglycerides in humans, a condition known as
hypertriglyceridemia (HTG), a form of dyslipidemia (or disorder of lipid
metabolism). Very high triglycerides have been linked to a number of
cardiovascular diseases. Omacor® is also approved in key European and certain
Asian markets for the secondary prevention of post-myocardial infarction, or
Post-MI, the period following the initial survival of a heart attack.
Omacor®/LovazaTM has been demonstrated in a number of clinical trials to be a
potent triglyceride-lowering agent as a monotherapy. It has been documented to
be efficacious, safe, and highly complementary to other lipid-lowering agents,
such as statins. In addition, Pronova BioPharma is involved in various projects
to develop Omacor®/LovazaTM in a number of cardiovascular indications, including
as a combination therapy with statins for mixed dyslipidemia which management
believe represents a major market opportunity for the Company.
Pronova BioPharma's global network of license and distribution partners
includes: GlaxoSmithKline PLC (USA), Takeda Pharmaceutical (Japan), Prospa
(Italy) and Abbott (UK, Germany and others). The combined sales force from this
network, focused on the sale of Omacor®/LovazaTM, is approximately 2,650 sales
representatives.
Omacor®/LovazaTM was launched in 2005 in the USA and in major European markets,
such as France and Spain. IMS Health reports that global end-user sales of the
product have increased from USD 144 million in 2005 to USD 1.1 billion in 2009.
Pronova BioPharma had revenues of NOK 1 790 million and EBITDA of NOK 823
million in 2009. The company is listed at Oslo Børs.
See www.pronova.com for more information.
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
[HUG#1445791]
Presentation 21 September 2010:
http://hugin.info/137506/R/1445791/388955.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pronova BioPharma ASA via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 21.09.2010 - 18:01 Uhr
Sprache: Deutsch
News-ID 42889
Anzahl Zeichen: 0
contact information:
Town:
Lysaker
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 211 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Presentation at the UBS Global Life Sciences Conference 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
Pronova BioPharma ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
